Temporal relationship between V1V2 variation, macrophage replication, and coreceptor adaptation during HIV-1 disease progression

AIDS

Volumn 16, Issue 14, 2002, Pages 1887-1898

  Masciotra, Silvina ^a   Owen, Sherry M ^a   Rudolph, Donna ^a   Yang, Chunfu ^a   Wang, Bin ^b   Saksena, Nitin ^b   Spira, Thomas ^a   Dhawan, Subhash ^c   Lal, Renu B ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Disease progression; HIV 1; V1V2 extension

Indexed keywords

AMINO ACID; CHEMOKINE RECEPTOR CCR5; VIRUS ENVELOPE PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; AUSTRALIA; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS ISOLATION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

CHRONIC DISEASE; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HOMOSEXUALITY, MALE; HUMANS; MACROPHAGES; MALE; T-LYMPHOCYTES; VIRAL LOAD; VIRUS REPLICATION;

EID: 0037183931     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200209270-00005     Document Type: Article

References (51)

1. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis and therapy. Science 1995, 267:483-489.
2. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-534.
3. Stevenson M. Molecular mechanisms for the regulation of HIV replication, persistence and latency. AIDS 1997, 11:S25-S33.
4. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism and disease. Annu Rev Immunol 1999, 17:657-700.
5. Hogan CM, Hammer SM. Host determinants in HIV infection and disease I: Cellular and humoral immune responses. Ann Intern Med 2001, 134:761-776.
6. Hogan CM, Hammer SM. Host determinants in HIV infection and disease II: genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001, 134:978-996.
7. Pantaleo G, Menzo S, Vaccarezza M, et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
8. Wang N, Zhu TF, Ho DD. Sequence diversity of V1 and V2 domains of gp120 from HIV-1: lack of correlation with viral phenotype. J Virol 1995, 69:2708-2715.
9. Wolinsky SM, Korber BTM, Neumann AU, et al. Adaptive evolution of HIV-1 during natural course of infection. Science 1996, 272:637-642.
10. Delwart EL, Pan H, Sheppard HW, et al. Slower evolution of HIV-1 quasispecies during progression to AIDS. J Virol 1997, 17:7498-7505.
11. Zhang L, Huang Y, Yuan H, Tuttleton S, Ho DD. Genetic characterization of vif, vpr, and vpu sequences from long-term survivors of HIV-1 infection. Virology 1997, 228:340-349.
12. Shankarappa R, Gupta P, Learn GJ, et al. Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology. 1998, 241:251-259.
13. Cornelissen M, Kuiken C, Zorgdrager F, Hartman S, Goudsmit J. Gross defects in the vpr and vpu genes of HIV type 1 cannot explain the differences in RNA copy number between long-term asymptomatics and progressors. AIDS Res Hum Retroviruses 1997, 13:247-253.
14. Yamada T, Iwamoto A. Comparison of proviral accessory genes between long-term nonprogressors and progressors of human immunodeficiency virus type 1 infection. Arch Virol 2000, 145:1021-1027.
15. Rhodes DI, Ashton L, Solomon A, et al. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression. Australian long-term nonprogressor study group. J Virol 2000, 74:10581-10588.
16. Subbramania RA, Cohen EA. Molecular biology of the human immunodeficiency virus accessory proteins. J Virol 1994, 68:6831-6835.
17. Rogel ME, Wu LI, Emerman M. The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 1995, 69:882-888.
18. Subbramanian RA, Kessous-Elbaz A, Lodge R, et al. Human immunodeficiency virus type 1 vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998, 187:1103-1111.
19. Hrimech M, Yao X, Bachand F, Rougeau N, Cohen EA. Human immunodeficiency virus type 1(HIV-1) vpr functions as an immediate-early protein during HIV-1 infection. J Virol 1999, 73:4101-4109.
20. Shen A, Siliciano JD, Pierson TC, Buck CB, Silician RF. Establishment of latent HIV-1 infection of resting CD4+ T lymphocytes does not require inactivation of vpr. Virology 2000, 278:227-233.
21. Nakaya T, Fujinaga K, Kishi M, et al. Nonsense mutations in the vpr gene of HIV-1 during in vitro virus passage and in HIV-1 carrier-derived peripheral blood mononuclear cells. FEBS Letters 1994, 354:17-22.
22. Cornelissen M, Hogervorst E, Zorgdrager F, Hartman S, Goudsmit J. Maintenance of syncytium-inducing phenotype of HIV type 1 is associated with positively charged residues in the HIV-1 gp120 domain without fixed positions, elongation or relocated N-linked glycosylation site. AIDS Res Hum Retrovir 1995, 11:1169-1175.
23. Fouchier RAM, Broersen SM, Brouwer M, et al. Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. AIDS Res Hum Retrovir 1995, 11:1473-1478.
24. Wang N, Zhu TF, Ho DD. Sequence diversity of V1 and V2 domains of gp120 from HIV-1: lack of correlation with viral phenotypes. J Virol 1995, 69:2708-22715.
25. Rizzuto C, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein stucture involved in chemokine receptor binding. Science 1998, 280:1949-1953.
26. Wyatt R, Moore J, Accola M, Desjardin E, Robinson J, Sodrosk,i J. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120epitopes induced by receptor binding. J Virol 1995, 69:5723-5733.
27. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
28. Maeda Y, Foda M, Matsushita S, Harada S. Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1α. J Virol 2000, 74:1787-1793.
29. Koito A, Harrowe G, Levy JA, Cheng-Mayer C. Functional role of the V1/V2 region of human immunodeficiency virus type1 envelope glycoprotein in infection of primary macrophages and soluble CD4 neutralization. J Virol 1994, 68:2253-2259.
30. Ly A, Stamatatos L. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol 2000, 74:6769-6776.
31. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Joseph S. Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 2001, 75:3435-3443.
32. Morikita T, Maeda Y, Fujii S, Matsushita S, Obaru K, Takatsuki K. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism. AIDS Res Hum Retrovir 1997, 13:1291-1299.
33. Cao J, Sullivan N, Desjardin E, et al. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997, 71:9808-9812.
34. Shioda T, Oka S, Xin X, et al. In vivo sequence variability of human immunodeficiency virus type 1 envelope gp120 gene: association of V2 extension with slow disease progression. J Virol 1997, 71:4871-4881.
35. Connor RL, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997, 185:621-628.
36. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression. Nat Med 1997, 3:1259-1265.
37. Xiao L, Rudolph DL, Owen SM, Spira TJ, Lal RB. Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression. AIDS 1998, 12:F137-F143.
38. Glushakova S, Grivel J-C, Fitzgerald W, Slywester A, Zimmerberg J, Margolis LB. Evidence for the HIV-1 phenotype switch as a causal factor in acquired immunodeficiency. Nat Med 1998, 4:346-349.
39. Fang Y, Wang Z, Vlabov D, Markham RB, Farzadegan H, Margolick JB. Infection with dual-tropic human immunodeficiency virus type 1 variants associated with rapid total T cell decline and disease progression in injection drug users. J Infect Dis 1998, 178:388-396.
40. Esté JA, Cabrera C, Blanco J, et al. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to X5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999, 73:5577-5585.
41. Fishbein DB, Kaplan JE, Spira TJ, et al. Unexplained lymphadeno pathy in homosexual men. JAMA 1985, 254:621-628.
42. Butera ST, Folks TM. Application of latent HIV-1 infected cellular models to therapeutic intervention. AIDS Res Hum Retrovir 1992, 8:991-995.
43. Wang B, Spira T, Owen S, Lal RB, Saksena NK. HIV-1 strains from a cohort of American subiects reveal the presence of a V2 region extension unique to slow progressors and non-progressors. AIDS 2000, 14:213-223.
44. Lafrenie RM, Wahl LM, Epstein JS, Yamada KM, Dhawan S. Activation of monocytes by HIV-Tat treatment is mediated by cytokine expression. J Immunol 1997, 159:4077-4083.
45. Jansson M, Backstrom E, Scarlatti G. Length polymorphism of glycoprotein 120 V2 region in relation to biological phenotypes and coreceptor usage of primary HIV type 1 isolates. AIDS Res Hum Retrovir 2001, 15:1405-1414.
46. Fox DG, Balfe R Palmer CP, May JC, Arnold C, McKeating JA. Length polymorphism within the second variable region of the human immunodeficiencyvirus type 1 envelope glycoprotein affects accessibility of the receptor binding site. J Virol 1997, 71:759-765.
47. Koita A, Stamatatos L, Cheng-Mayer C. Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology 1995, 206:878-884.
48. Ross TM, Cullen BR. The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR5 tropic V3 loop. Proc Natl Acad Sci USA 1998, 95:7682-7686.
49. Lu Z, Berson JF, Chen Y, et al. Evolution of HIV-1 coreceptor usage through interactions with distinct CCR5 and CXCR4 domains. Proc Natl Acad Sci USA 1997, 94:6426-6431.
50. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, Martin MA. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 1998, 72:2509-2515.
51. Xiao L, Owen SM, Goldman I, et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR5 usage. Virology 1998, 240:83-92.